William K Schmidt - JoVE Visualize

Showing results (11-20 of 19) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 19 results.

Pain|March 11, 2016

A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton's neuromaClaudia M Campbell, Eric Diamond, William K Schmidt, et al.

Frontiers in Pharmacology|June 20, 2019

Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine OsteoarthritisCindy B McReynolds, Sung Hee Hwang, Jun Yang, et al.

Diseases of the Colon and Rectum|May 21, 2005

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgeryConor P Delaney, James L Weese, Neil H Hyman, et al.

Cellular and Molecular Neurobiology|February 29, 2020

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in RodentsCaroline M Kopruszinski, Juliana Swiokla, Yeon Sun Lee, et al.

Pain|June 12, 2012

Randomized control trial of topical clonidine for treatment of painful diabetic neuropathyClaudia M Campbell, Mark S Kipnes, Bruce C Stouch, et al.

The Journal of Pain|March 18, 2005

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trialDaniel M Paulson, Daniel T Kennedy, Roger A Donovick, et al.

Journal of Medicinal Chemistry|February 8, 2021

Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid AlternativeBruce D Hammock, Cindy B McReynolds, Karen Wagner, et al.

Clinical and Translational Science|September 20, 2024

Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteersWilliam K Schmidt, Irene Cortés-Puch, Cindy B McReynolds, et al.

Pain|October 23, 2013

Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injuryJulien Mamet, Michael Klukinov, Tony L Yaksh, et al.

Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 19 results.

Pain|March 11, 2016

A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton's neuromaClaudia M Campbell, Eric Diamond, William K Schmidt, et al.

Frontiers in Pharmacology|June 20, 2019

Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine OsteoarthritisCindy B McReynolds, Sung Hee Hwang, Jun Yang, et al.

Diseases of the Colon and Rectum|May 21, 2005

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgeryConor P Delaney, James L Weese, Neil H Hyman, et al.

Cellular and Molecular Neurobiology|February 29, 2020

Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in RodentsCaroline M Kopruszinski, Juliana Swiokla, Yeon Sun Lee, et al.

Pain|June 12, 2012

Randomized control trial of topical clonidine for treatment of painful diabetic neuropathyClaudia M Campbell, Mark S Kipnes, Bruce C Stouch, et al.

The Journal of Pain|March 18, 2005

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trialDaniel M Paulson, Daniel T Kennedy, Roger A Donovick, et al.

Journal of Medicinal Chemistry|February 8, 2021

Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid AlternativeBruce D Hammock, Cindy B McReynolds, Karen Wagner, et al.

Clinical and Translational Science|September 20, 2024

Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteersWilliam K Schmidt, Irene Cortés-Puch, Cindy B McReynolds, et al.

Pain|October 23, 2013

Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injuryJulien Mamet, Michael Klukinov, Tony L Yaksh, et al.

Pageof 2